Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 205-710-6 | CAS number: 148-18-5
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Dermal absorption
Administrative data
- Endpoint:
- dermal absorption in vitro / ex vivo
- Type of information:
- experimental study
- Adequacy of study:
- supporting study
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 010
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 428 (Skin Absorption: In Vitro Method)
- GLP compliance:
- yes (incl. QA statement)
Test material
- Reference substance name:
- Sodium diethyldithiocarbamate
- EC Number:
- 205-710-6
- EC Name:
- Sodium diethyldithiocarbamate
- Cas Number:
- 148-18-5
- Molecular formula:
- C5H11NS2.Na
- IUPAC Name:
- sodium (diethylcarbamothioyl)sulfanide
Constituent 1
- Radiolabelling:
- yes
- Remarks:
- 14C
Administration / exposure
- Type of coverage:
- other: open (experiment 1) and semi-occlusive (experiment 2)
- Vehicle:
- water
- Duration of exposure:
- 8 hours with 16 hours post-exposure
- Doses:
- 2433 ± 27 and 236 ± 3 µg x cm-2 in experiment 1 (doses A and B, 23.4% and 2.34% solutions of SDEC)
2469 ± 16 µg x cm-2 in experiment 2 (23.4% solution of SDEC) - Details on study design:
- DOSE PREPARATION
- Method for preparation of dose suspensions: For dose preparation A, the proper amount of [14C]SDEC dissolved in an adequate solvent, was transferred to a vial and the solvent was evaporated under N2 gas until dryness. Subsequently, the proper amount of Perkacit SDEC liq-w26% formulation was added and mixed.
For dose preparation B, the proper amount of [14C]SDEC, was transferred to a vial and the solvent evaporated under N2 gas until dryness. The proper amount of Perkacit SDEC liq-w26% formulation, 1:10 diluted with demineralised water, was added and mixed.
- Method of storage: The dose preparations were kept at ambient temperature until application.
APPLICATION OF DOSE: The dose preparations were applied with a pipette tip and spread evenly on the skin surface within the donor compartment (10 µL.cm-2). The dose preparations were carefully mixed before each administration. The concentration and homogeneity of [14C]SDEC in the dose preparations were checked by taking aliquots just before and directly after dosing. The aliquots are divided in the net dose applied and the amount of radioactivity remaining in the pipette tip, while their sum is considered the gross dose used to determine the concentration and homogeneity. The coefficient of variation (CV) was found to be lower than 10 % (i.e. 0.8 % (A), 1.0 % (B) and 2.0 %, and therefore considered sufficient. The radiochemical purity of [14C]SDEC in the dose preparations was found to be > 98 %
TEST SITE
- Area of exposure: a net volume of approximately 6.4 µL of the dose preparations was applied on each skin membrane (0.64 cm2).
REMOVAL OF TEST SUBSTANCE
- Washing procedures and type of cleansing agent: After an exposure period the unabsorbed test substance was removed from the application site using a mild soap solution (i.e. a 3 % Teepol in water) and cotton swabs.
- Time after start of exposure: 8 h
ANALYSIS
- Method type for identification: liquid scintillation counting - Details on in vitro test system (if applicable):
- SKIN PREPARATION
- Source of skin: human skin from three donors, obtained directly after surgery
- Ethical approval if human skin: yes
- Type of skin: derived from abdomen and/or breast
- Preparation technique: thawed from frozen skin samples. Subcutaneous fat was removed and the skin was stored in aluminium foil at < −18 °C until use. The skin of donor 1 was stored overnight at 2 – 10 °C before subcutaneous fat was removed.
- Thickness of skin (in mm): ca 400 µm
- Membrane integrity check: yes
- Storage conditions: frozen
PRINCIPLES OF ASSAY
- Diffusion cell: 9 mm flow-through automated diffusion cells (PermeGear Inc., Riegelsville, PA, USA).
- Receptor fluid: phosphate buffered saline (PBS).
- Solubility of test substance in receptor fluid: freely soluble
- Flow-through system: yes
- Test temperature: 32 ± 1 ºC
- Humidity: ambient
- Occlusion: no (experiment 1) or semi-occlusive under charcoal filter (experiment 2)
- Reference substance(s): [3H]H2O
Results and discussion
- Total recovery:
- - Total recovery: The mean recovery of [14C]SDEC in human skin in the first experiment was 83.4 ± 3.1 % and 49.5 ± 5.3 % for the undiluted (experiment A) and 1:10 dilution (experiment B) solution, respectively.
An additional study was performed to try to explain the low recoveries that were found.
As a result from the eight hour exposure of the test solution to a temperature >30 °C, volatiles may have been formed. Therefore, dermal absorption of SDEC from the undiluted Perkacit SDEC liq-w26% was tested again while the donor compartment was kept semi-occluded by a charcoal filter. Furthermore, NaOH was added to increase pH and stabilize the test compound in the various fractions and prevent the possible formation of insoluble complexes.
The (semi-) occlusive conditions result in an increase in dermal absorption which was expected as occlusive conditions are known to enhance dermal absorption. The mean absorption of [14C]SDEC from the undiluted Perkacit SDEC liq-w26% formulation into the receptor fluid under semi-occlusive conditions increased to 170.14 µg.cm-2 after 24 hours, representing 6.89 % of the dose applied. The mean maximal flux increased to 36.63 µg x cm-2 x h-1. The lag time was comparable, i.e. 5.1 h.
The mean total absorption was 7.48 % of the dose applied and the mean total recovery improved to 92.9 ± 4.2 %.
In the second experiment, performed under semi-occlusive conditions, negligible amounts were recovered from the charcoal filter. The formation of volatiles therefore does not explain the low recoveries in the first experiment. A substantial increase in recovery resulted from the change in extraction procedure for the cotton swabs, using 0.1 M NaOH in water. It appears that the dermal absorption data obtained in experiment 1 are therefore reliable and that the missing radio-activity which caused the low recoveries values should be contributed to the skin wash (i.e. the cotton swabs).
Percutaneous absorptionopen allclose all
- Dose:
- 2469 ± 16.01 µg/cm2
- Parameter:
- percentage
- Absorption:
- 7.48 %
- Remarks on result:
- other: 8 hr
- Remarks:
- semi-occlusive conditions
- Dose:
- 2433 ± 27 µg/cm2
- Parameter:
- percentage
- Absorption:
- 4.13 %
- Remarks on result:
- other: 8 hr
- Remarks:
- non-occlusive conditions
Any other information on results incl. tables
In the first experiment, the mean absorption of [14C]SDEC from an undiluted Perkacit SDEC liq-w26% formulation into the receptor fluid after 24 hours was 92.34 µg.cm-2, representing 3.77 % of the dose applied. The mean maximal flux for the absorption of SDEC through human skin was 27.13 µg.cm-2.h-1. The lag time was 4.5 h.
The mean absorption of [14C]SDEC from a 10-times diluted Perkacit SDEC liq-w26% formulation into the receptor fluid after 24 hours was 2.21 µg.cm-2, representing 0.94 % of the dose applied. The mean maximal flux for the absorption of SDEC through human skin was 0.31 µg.cm-2h-1. The lag time was 2.7 h. For the 10-times diluted Perkacit solution, a clear difference in dermal absorption between donors was observed.
The mean total absorption, defined as the compound-related radioactivity present in the receptor fluid, the receptor compartment wash and the skin membranes but excluding the tape strips was 4.13 % (undiluted Perkacit) and 1.49 % (10-times diluted Perkacit) of the dose applied.
The mean recovery of [14C]SDEC in human skin was 83.4 ± 3.1 % and 49.5 ± 5.3 % for the undiluted and 1:10 dilution solution, respectively.
In the second experiment, performed under semi-occlusive conditions, negligible amounts were recovered from the charcoal filter. The formation of volatiles therefore does not explain the low recoveries in the first experiment. A substantial increase in recovery resulted from the change in extraction procedure for the cotton swabs, using 0.1 M NaOH in water. It appears that the dermal absorption data obtained in experiment 1 are therefore reliable and that the missing radio-activity which caused the low recoveries values should be contributed to the skin wash (i.e. the cotton swabs).
It should be noted that, most likely as a result from the high pH of the Perkacit formulation, both the undiluted and diluted solutions appeared to have interfered with the integrity of the stratum corneum and, consequently, its barrier properties. This effect was confirmed by the fact that tape stripping was very difficult and is illustrated by the increasing relative absorption with increasing dose levels; in general, relative absorption decreases with increasing dose levels.
Applicant's summary and conclusion
- Conclusions:
- The in vitro measured dermal absorption of SDEC (26% solution) was between 4.1 and 7.5% of the initially applied concentration. As a result of the high pH,the test material seems to interfere with the integrity of the stratum corneum and, consequently, its barrier properties.
- Executive summary:
A dermal penetration study in vitro using human skin was conducted to estimate the dermal absorption of SDEC through human skin. The study was performed according to OECD Guideline 428 using breast or abdomen human skin from 3 donors, removed directly after surgery. The test substance (26% aqueous solution SDEC) was tested at two target concentrations, i. e. a 23.4 % (w/w) solution in water (ca.253 g/L, dose A) and a ten-fold dilution in water to 2.34 % (ca. 2.53g/L, dose B). The objective of the study was to elucidate the extent of percutaneous absorption of the compound-related radioactivity. The contact time was 8 hours, i. e. a normal working day and the post exposure time was 16 hours. In addition to the amount of [14C]-SDEC in the receptor fluid, the residues remaining in/on the skin membranes and in the stratum corneum (16 h post exposure) were determined. The study was performed in flow-through diffusion cells. The mean total absorption was 4.13 % (undiluted Perkacit) and 1.49 % (10-times diluted Perkacit) of the dose applied. The mean recovery of [14C]-SDEC in human skin was 83.4 ± 3.1 % and 49.5 ± 5.3 % for the undiluted and 1:10 dilution solution, respectively.The experiment was repeated under semi-occlusive conditions, because of low radioactivity recoveries. The (semi-) occlusive conditions resulted in an increase in the mean total dermal absorption, that was 7.48 % of the dose applied the mean total recovery improved to 92.9 ± 4.2 %. In the second experiment, negligible amounts were recovered from the charcoal filter. It appears that the dermal absorption data obtained in experiment 1 are therefore reliable and that the missing radio-activity which caused the low recoveries values should be contributed to the skin wash (i. e. the cotton swabs).
As a result of the high pH, both the undiluted (26% solution of SDEC) and diluted (10 X 26% solution) solutions appeared to have interfered with the integrity of the stratum corneum and, consequently, its barrier properties. This effect was confirmed by the fact that tape stripping was very difficult and is illustrated by the increasing relative absorption with increasing dose levels; in general, relative absorption decreases with increasing dose levels.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.